Broadcom named strategic vendor for Walmart virtualization solutions
FLORHAM PARK, N.J. - Conduent Incorporated (NASDAQ:CNDT), a provider of business solutions and services, has announced that Ireland’s Health Service Executive (HSE) will be using its Maven® Disease Surveillance & Outbreak Management System. The HSE, responsible for public health and social care services in Ireland, has entered into a five-year contract with Conduent for the implementation of Maven, aiming to enhance disease tracking and management capabilities.
The Maven platform, which is cloud-hosted, is designed to reduce manual data entry and improve the coordination of data among healthcare professionals. This system is set to replace the HSE’s previous surveillance system, offering a more efficient approach to managing public health threats by automating the generation of disease events from case or laboratory reports.
Dr. John Cuddihy, National Director of Public Health at HSE, emphasized the importance of the Maven system in providing a modern, national platform for early detection and response to health events. According to Dr. Cuddihy, this will enable the transformation of raw data into actionable intelligence, facilitating quicker and more coordinated public health responses.
The adoption of Maven by Ireland marks its first foray into the European Union, joining other public health deployments in the United States, the United Kingdom, and Australia. The system is currently utilized by 28 government agencies worldwide, demonstrating its global reach and the trust placed in its capabilities to manage public health emergencies. While trading at a modest P/E ratio of 1.33 and maintaining a healthy current ratio of 1.68, InvestingPro subscribers can access 11 additional key insights about Conduent’s financial health and growth prospects through the platform’s comprehensive Pro Research Report.
Conduent’s Maven system has been in use for over two decades and supports the management of various communicable and non-communicable diseases, including COVID-19, C. auris, Mpox, Ebola, Zika, measles, tuberculosis, HIV/STDs, and influenza. The company provides online and in-person training for the system and facilitates a Maven Users Group that encourages collaboration and exchange of best practices among public health officials.
Anna Sever, President of Government Solutions at Conduent, expressed pride in Ireland joining the Maven user community. She highlighted that the implementation of Maven aims to equip the HSE with essential tools for protecting citizens against infectious diseases and delivering long-term value. With the stock currently trading near its 52-week low of $2.94, investors seeking detailed analysis can access Conduent’s complete financial health metrics and growth potential through InvestingPro’s extensive research tools and expert insights.
This information is based on a press release statement from Conduent Incorporated.
In other recent news, Conduent Inc. reported its Q4 2024 earnings, revealing an earnings per share (EPS) of -$0.15, which missed the forecasted -$0.12. The company’s revenue also fell short of expectations, coming in at $800 million compared to the anticipated $806.33 million. For the full year, Conduent’s revenue declined by 4.3% to $3.176 billion, with adjusted EBITDA dropping to $124 million from $247 million in 2023. Despite these declines, the company maintained an adjusted EBITDA margin of 3.9%, which was at the higher end of expectations. Conduent has set a revenue guidance range for 2025 between $3.100 billion and $3.250 billion, with an adjusted EBITDA margin expected between 4.5% and 5.5%. The company is focusing on leveraging AI technologies and expanding offshore capabilities, with plans to achieve an adjusted EBITDA margin exit rate of around 8% by the end of 2025. CEO Cliff Skelton emphasized the company’s strategic direction and focus on financial stability and growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.